APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Asthma Short Acting Beta Agonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Asthma Short Acting Beta Agonists Market Outlook and Growth Opportunities 2026

23 December 2025196 pages

Choose your research edition.

Industry ResearchAnti-Asthma Short Acting Beta Agonists Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Asthma Short Acting Beta Agonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-Asthma Short Acting Beta Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Asthma Short Acting Beta Agonists Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Asthma Short Acting Beta Agonists Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Anti-Asthma Short Acting Beta Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Asthma Short Acting Beta Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Asthma Short Acting Beta Agonists market include Chia Tai Tianqing Pharmaceutical Group, Teva Pharmaceutical, Sichuan Puretech Pharmaceutical, Sanofi, Novartis, Shandong Lunan Pharmaceutical, Joincare Pharmaceutical Group Industry, Pfizer and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Asthma Short Acting Beta Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Asthma Short Acting Beta Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Asthma Short Acting Beta Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Asthma Short Acting Beta Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Asthma Short Acting Beta Agonists Segment by Company

Chia Tai Tianqing Pharmaceutical Group

Teva Pharmaceutical

Sichuan Puretech Pharmaceutical

Sanofi

Novartis

Shandong Lunan Pharmaceutical

Joincare Pharmaceutical Group Industry

Pfizer

Jiangsu Hengrui Pharmaceuticals

GlaxoSmithKline

AstraZeneca

Viatris

Boehringer Ingelheim

Anti-Asthma Short Acting Beta Agonists Segment by Type

Non-Selective Beta Receptor Agonists

Selective Beta 2 Receptor Agonists

Anti-Asthma Short Acting Beta Agonists Segment by Application

Pharmacy

Hospital

Clinic

Others

Anti-Asthma Short Acting Beta Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Asthma Short Acting Beta Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Asthma Short Acting Beta Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Asthma Short Acting Beta Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Asthma Short Acting Beta Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Asthma Short Acting Beta Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Asthma Short Acting Beta Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Asthma Short Acting Beta Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Asthma Short Acting Beta Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Asthma Short Acting Beta Agonists industry.

Chapter 3: Detailed analysis of Anti-Asthma Short Acting Beta Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Asthma Short Acting Beta Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Asthma Short Acting Beta Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Asthma Short Acting Beta Agonists Industry Trends Table 2. Anti-Asthma Short Acting Beta Agonists Industry Drivers Table 3. Anti-Asthma Short Acting Beta Agonists Industry Opportunities and Challenges Table 4. Anti-Asthma Short Acting Beta Agonists Industry Restraints Table 5. Global Anti-Asthma Short Acting Beta Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Asthma Short Acting Beta Agonists Revenue Share by Company (2021-2026) Table 7. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Company (units) & (2021-2026) Table 8. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Asthma Short Acting Beta Agonists Average Price (USD/unit) of Company (2021-2026) Table 10. Global Anti-Asthma Short Acting Beta Agonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Asthma Short Acting Beta Agonists Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Asthma Short Acting Beta Agonists Company, Product Type & Application Table 13. Global Anti-Asthma Short Acting Beta Agonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Asthma Short Acting Beta Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Non-Selective Beta Receptor Agonists Table 18. Significant Companies of Selective Beta 2 Receptor Agonists Table 19. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type (2021-2026) & (units) Table 21. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type (2027-2032) & (units) Table 22. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Type (2021-2026) Table 23. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Type (2027-2032) Table 24. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type (2021-2026) Table 28. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmacy Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 34. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application (2021-2026) & (units) Table 35. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application (2027-2032) & (units) Table 36. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Application (2021-2026) Table 37. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Application (2027-2032) Table 38. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application (2021-2026) Table 42. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application (2027-2032) Table 43. Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021 VS 2025 VS 2032 (units) Table 44. Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2021-2026) & (units) Table 45. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Region (2021-2026) Table 46. Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2027-2032) & (units) Table 47. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Region (2027-2032) Table 48. Global Anti-Asthma Short Acting Beta Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Region (2021-2026) Table 51. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Region (2027-2032) Table 53. Global Anti-Asthma Short Acting Beta Agonists Market Average Price (USD/unit) by Region (2021-2026) Table 54. Global Anti-Asthma Short Acting Beta Agonists Market Average Price (USD/unit) by Region (2027-2032) Table 55. Global Anti-Asthma Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032 (units) Table 56. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 58. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2026) Table 59. Global Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 60. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2027-2032) Table 61. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Anti-Asthma Short Acting Beta Agonists Sales Value Market Share by Country (2021-2026) Table 63. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Anti-Asthma Short Acting Beta Agonists Sales Value Market Share by Country (2027-2032) Table 65. Chia Tai Tianqing Pharmaceutical Group Company Information Table 66. Chia Tai Tianqing Pharmaceutical Group Business Overview Table 67. Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 69. Chia Tai Tianqing Pharmaceutical Group Recent Development Table 70. Teva Pharmaceutical Company Information Table 71. Teva Pharmaceutical Business Overview Table 72. Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 74. Teva Pharmaceutical Recent Development Table 75. Sichuan Puretech Pharmaceutical Company Information Table 76. Sichuan Puretech Pharmaceutical Business Overview Table 77. Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 79. Sichuan Puretech Pharmaceutical Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Sanofi Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 84. Sanofi Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Novartis Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 89. Novartis Recent Development Table 90. Shandong Lunan Pharmaceutical Company Information Table 91. Shandong Lunan Pharmaceutical Business Overview Table 92. Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 94. Shandong Lunan Pharmaceutical Recent Development Table 95. Joincare Pharmaceutical Group Industry Company Information Table 96. Joincare Pharmaceutical Group Industry Business Overview Table 97. Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 99. Joincare Pharmaceutical Group Industry Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Pfizer Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 104. Pfizer Recent Development Table 105. Jiangsu Hengrui Pharmaceuticals Company Information Table 106. Jiangsu Hengrui Pharmaceuticals Business Overview Table 107. Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 109. Jiangsu Hengrui Pharmaceuticals Recent Development Table 110. GlaxoSmithKline Company Information Table 111. GlaxoSmithKline Business Overview Table 112. GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 114. GlaxoSmithKline Recent Development Table 115. AstraZeneca Company Information Table 116. AstraZeneca Business Overview Table 117. AstraZeneca Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. AstraZeneca Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 119. AstraZeneca Recent Development Table 120. Viatris Company Information Table 121. Viatris Business Overview Table 122. Viatris Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Viatris Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 124. Viatris Recent Development Table 125. Boehringer Ingelheim Company Information Table 126. Boehringer Ingelheim Business Overview Table 127. Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 129. Boehringer Ingelheim Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Anti-Asthma Short Acting Beta Agonists Distributors List Table 133. Anti-Asthma Short Acting Beta Agonists Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Anti-Asthma Short Acting Beta Agonists Product Image Figure 2. Global Anti-Asthma Short Acting Beta Agonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Asthma Short Acting Beta Agonists Sales (2021-2032) & (units) Figure 5. Global Anti-Asthma Short Acting Beta Agonists Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Anti-Asthma Short Acting Beta Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Non-Selective Beta Receptor Agonists Image Figure 10. Selective Beta 2 Receptor Agonists Image Figure 11. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type (2021-2032) Figure 17. Pharmacy Image Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 22. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Application (2021-2032) Figure 24. Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application (2021-2032) Figure 27. Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 28. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Anti-Asthma Short Acting Beta Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 32. North America Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 38. South America Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Anti-Asthma Short Acting Beta Agonists Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Anti-Asthma Short Acting Beta Agonists Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Non-Selective Beta Receptor Agonists
  • Selective Beta 2 Receptor Agonists
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chia Tai Tianqing Pharmaceutical Group
  • Teva Pharmaceutical
  • Sichuan Puretech Pharmaceutical
  • Sanofi
  • Novartis
  • Shandong Lunan Pharmaceutical
  • Joincare Pharmaceutical Group Industry
  • Pfizer
  • Jiangsu Hengrui Pharmaceuticals
  • GlaxoSmithKline
  • AstraZeneca
  • Viatris
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Asthma Short Acting Beta Agonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Asthma Short Acting Beta Agonists Market Dynamics
  1. 2.1 Anti-Asthma Short Acting Beta Agonists Industry Trends
  2. 2.2 Anti-Asthma Short Acting Beta Agonists Industry Drivers
  3. 2.3 Anti-Asthma Short Acting Beta Agonists Industry Opportunities and Challenges
  4. 2.4 Anti-Asthma Short Acting Beta Agonists Industry Restraints
3 Anti-Asthma Short Acting Beta Agonists Market by Company
  1. 3.1 Global Anti-Asthma Short Acting Beta Agonists Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Asthma Short Acting Beta Agonists Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Asthma Short Acting Beta Agonists Company Ranking (2024-2026)
  6. 3.6 Global Anti-Asthma Short Acting Beta Agonists Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Asthma Short Acting Beta Agonists Company Product Type and Application
  8. 3.8 Global Anti-Asthma Short Acting Beta Agonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Asthma Short Acting Beta Agonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Asthma Short Acting Beta Agonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Asthma Short Acting Beta Agonists Market by Type
  1. 4.1 Anti-Asthma Short Acting Beta Agonists Type Introduction
  2. 4.1.1 Non-Selective Beta Receptor Agonists
  3. 4.1.2 Selective Beta 2 Receptor Agonists
  4. 4.2 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type
  5. 4.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type
  9. 4.3.1 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type (2021-2032)
5 Anti-Asthma Short Acting Beta Agonists Market by Application
  1. 5.1 Anti-Asthma Short Acting Beta Agonists Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application
  7. 5.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Anti-Asthma Short Acting Beta Agonists Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application
  11. 5.3.1 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Application (2021-2032)
  13. 5.3.3 Global Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application (2021-2032)
6 Anti-Asthma Short Acting Beta Agonists Regional Sales and Value Analysis
  1. 6.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2027-2032)
  5. 6.3 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Asthma Short Acting Beta Agonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Asthma Short Acting Beta Agonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Asthma Short Acting Beta Agonists Sales Value Share by Country, 2025 VS 2032
7 Anti-Asthma Short Acting Beta Agonists Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032)
  6. 7.4 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Asthma Short Acting Beta Agonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Asthma Short Acting Beta Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical Group
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments
  7. 8.2 Teva Pharmaceutical
  8. 8.2.1 Teva Pharmaceutical Company Information
  9. 8.2.2 Teva Pharmaceutical Business Overview
  10. 8.2.3 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Recent Developments
  13. 8.3 Sichuan Puretech Pharmaceutical
  14. 8.3.1 Sichuan Puretech Pharmaceutical Company Information
  15. 8.3.2 Sichuan Puretech Pharmaceutical Business Overview
  16. 8.3.3 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  18. 8.3.5 Sichuan Puretech Pharmaceutical Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Anti-Asthma Short Acting Beta Agonists Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Anti-Asthma Short Acting Beta Agonists Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Shandong Lunan Pharmaceutical
  32. 8.6.1 Shandong Lunan Pharmaceutical Company Information
  33. 8.6.2 Shandong Lunan Pharmaceutical Business Overview
  34. 8.6.3 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  36. 8.6.5 Shandong Lunan Pharmaceutical Recent Developments
  37. 8.7 Joincare Pharmaceutical Group Industry
  38. 8.7.1 Joincare Pharmaceutical Group Industry Company Information
  39. 8.7.2 Joincare Pharmaceutical Group Industry Business Overview
  40. 8.7.3 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Product Portfolio
  42. 8.7.5 Joincare Pharmaceutical Group Industry Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Anti-Asthma Short Acting Beta Agonists Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Anti-Asthma Short Acting Beta Agonists Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Viatris
  68. 8.12.1 Viatris Company Information
  69. 8.12.2 Viatris Business Overview
  70. 8.12.3 Viatris Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Viatris Anti-Asthma Short Acting Beta Agonists Product Portfolio
  72. 8.12.5 Viatris Recent Developments
  73. 8.13 Boehringer Ingelheim
  74. 8.13.1 Boehringer Ingelheim Company Information
  75. 8.13.2 Boehringer Ingelheim Business Overview
  76. 8.13.3 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Product Portfolio
  78. 8.13.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Asthma Short Acting Beta Agonists Value Chain Analysis
  2. 9.1.1 Anti-Asthma Short Acting Beta Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Asthma Short Acting Beta Agonists Sales Mode & Process
  6. 9.2 Anti-Asthma Short Acting Beta Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Asthma Short Acting Beta Agonists Distributors
  9. 9.2.3 Anti-Asthma Short Acting Beta Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst